The Paper reporter Li Xiaoxiao

  On February 14, the Hong Kong stock market Kintor Pharmaceutical (09939.HK) once rose nearly 35%, and as of press time, it rose nearly 25%, with a market value of over 4.7 billion Hong Kong dollars.

  On the news, on February 11, Kintor Pharma announced that the global multi-center Phase III clinical trial (NCT04869228) of proclutamide in the treatment of patients with mild to moderate COVID-19 has completed the first trial in China at Shenzhen Third People's Hospital. Enrollment and administration.

  Prokalutamide belongs to a new generation of androgen receptor (AR) antagonist. It was originally a class 1.1 innovative drug for the treatment of prostate cancer and advanced breast cancer. Kintor Pharmaceuticals developed and explored its use in the treatment of new coronary pneumonia. of oral medicines.

  Kintor Pharmaceuticals introduced in the announcement that the Phase III clinical trial of Prokalutamide is a randomized, double-blind, placebo-controlled, global multi-center study to explore the efficacy of Prokalutamide in the treatment of mild-to-moderate male patients with COVID-19. Efficacy and Safety.

  At present, the trial has completed the enrollment of nearly 200 subjects in countries such as Brazil, the Philippines and Malaysia.

China is one of the major participating countries in this phase III clinical trial, which was approved by the State Drug Administration on September 1, 2021.

Currently participating centers in China include Beijing Ditan Hospital, China-Japan Friendship Hospital, Shenzhen Third People's Hospital, Shanghai Public Health Clinical Center, Hangzhou Xixi Hospital, Chengdu Public Health Clinical Center and Suzhou Fifth People's Hospital Wait.

  The announcement also mentioned that the clinical trial (NCT05009732) of proclutamide for critically hospitalized patients with COVID-19 has fully initiated patient enrollment in the United States, Ukraine, and the Philippines, and is currently conducting pre-enrollment screening at the Chinese clinical center.

Related work in other countries participating in global multi-center clinical trials is also actively advancing.

  It is worth mentioning that on December 27, 2021, Kintor Pharma announced the progress of the Phase III clinical trial of proclutamide in the treatment of mild-to-moderate non-hospitalized patients with COVID-19, saying that according to the interim analysis data of 348 patients with COVID-19, due to The small number of events did not reach statistical significance, and the company plans to adjust the clinical trial protocol for patient recruitment.

The news sent shares in Kintor plunging 70%.